QPPV.COM KNOWLEDGE ASSESSMENT

Pivekimab Sunirine: Classification, Mechanism, Evidence and Pharmacovigilance

Test your understanding of the concepts covered by Pivekimab Sunirine: Classification, Mechanism, Evidence and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why should treatment history be retained in case records even though the U.S. indication is not restricted to one prior-treatment category?

Because prior treatment determines whether BPDCN can be diagnosed. Because treatment-naïve, relapsed/refractory, and transplant-pathway patients can have different competing risks and subsequent clinical courses. Because the indication requires a separate dose for every treatment line. Because treatment history is relevant only to efficacy analyses, not safety assessment.

Question 2 of 10 A safety reviewer is explaining the intended role of CD123 in pivekimab sunirine’s design. Which statement is most appropriate?

CD123 is the cytotoxic payload that directly damages DNA after infusion. CD123 is a cell-surface target that the antibody binds, supporting delivery of the cytotoxic component to target-expressing cells. CD123 is a diagnostic criterion that replaces clinical assessment of BPDCN. CD123 binding neutralises the payload and is intended to prevent cytotoxic activity.

Question 3 of 10 A patient develops oedema while receiving pivekimab sunirine. Which follow-up best reflects the article’s recommended approach?

Assume the oedema is hepatic VOD because both conditions can involve fluid retention. Document distribution and weight trajectory and evaluate hepatic, renal, cardiac, and disease-related explanations, along with relevant fluids and albumin status. Record oedema only if it occurs during an infusion. Attribute it to BPDCN without assessing other potential causes.

Question 4 of 10 Which statement about target-directed delivery is most appropriate for a safety communication?

CD123 targeting means the payload can affect only malignant cells. Targeting supports delivery to CD123-expressing cells but does not make exposure biologically confined to malignant cells. Targeting eliminates the possibility of systemic toxicity. The antibody prevents uptake of the conjugate after CD123 binding.

Question 5 of 10 Which aggregate safety review strategy is most aligned with the article?

Track VOD together with all other adverse events in one undifferentiated category. Review VOD, other serious hepatotoxicity, infusion reactions, clinically significant oedema, serious allergic reactions, severe cytopenic complications, and fatal cases separately. Review only events that occur during the infusion. Prioritise response outcomes and exclude serious safety cases from aggregate review.

Question 6 of 10 Why should treatment-naïve and relapsed/refractory CADENZA results be presented separately when describing benefit?

The cohorts had markedly different CR/CRc proportions and represent different clinical populations, so combining them can obscure clinically meaningful differences. The relapsed/refractory cohort was not part of the regulatory efficacy population. The treatment-naïve cohort had no response-duration data, making comparison impossible. The study was randomised between the two cohorts, so only pooled results are valid.

Question 7 of 10 A safety database captures the medicine name and adverse event but omits infusion dates, prior cytotoxic therapy, and subsequent transplantation. What is the main pharmacovigilance limitation?

The missing context makes it harder to distinguish ADC-related events from disease- and pathway-related complications and to interpret timing. The case is automatically invalid because every patient must undergo transplantation. The event can no longer be assessed because dose information is never useful for an ADC. The database can still establish causality from the event term alone.

Question 8 of 10 Which statement best reflects the U.S. indication described in the article?

It is limited to adults with treatment-naïve BPDCN. It covers adults with BPDCN and is not restricted in the approval wording to a single prior-treatment category. It covers adults with any CD123-expressing malignancy. It is limited to patients who are eligible for subsequent stem-cell transplantation.

Question 9 of 10 A report describes VOD after pivekimab sunirine treatment in a patient who later received transplant conditioning. What is the most appropriate initial case-assessment approach?

Use the date of the last pivekimab sunirine dose as the sole basis for assigning causality. Classify the event as transplant-related and exclude the ADC from the assessment. Reconstruct the sequence of ADC exposure, response, conditioning, transplantation, liver abnormalities, diagnostic work-up, and outcome. Treat the report as unassessable unless VOD began during the ADC infusion.

Question 10 of 10 Which description accurately characterises the CADENZA regulatory efficacy evidence presented in the article?

A randomised, double-blind comparison of pivekimab sunirine with standard therapy. A multicentre, open-label, single-arm study with a regulatory efficacy population of 33 treatment-naïve and 51 relapsed/refractory adults, without active CNS disease. A placebo-controlled study limited to adults with newly diagnosed BPDCN. An observational registry enrolling patients with active CNS disease only.

QPPV.com

Pivekimab Sunirine: Classification, Mechanism, Evidence and Pharmacovigilance

Cookie Settings